Business & Sales Plan

2. Introduction of the Company
 Core function is to import market medications
internationally
 Onco Care is built upon the philosophy of quality service,
reliability and added value.
 We have targeted a niche and neglected market i.e.
‘Oncology’
 It is basically a company that imports and markets Anti-
cancer medications from South Korea.

3. Mission
“Our mission is to provide safe ,
effective and affordable medicines
to millions of people who are in
need"

4. Organizational Hierarchy
NavaidM.Khan
CEO
Hamza Azeem
VP Marketing
Marketing Manager
Shayan Tejani
VP Sales
Mujtaba Sheikh
Product & Training Manager
Zainab Sarwar
RSM Karachi
RSM Multan
RSM Lahore
RSM Islamabad
RSM Peshawar
Sabah Ashraf
HR Manager
Zarlish Usmani
Finance Manager
Cashier
Business Analyst
Distribution Manager
Accountant
PersonalSecretary

5. Strategic Business Partners

6. PRODUCT PORTFOLIO

7. Azafrine Tablet
 Azafrine is used with other medications to
prevent rejection of a kidney transplant.
 It works by weakening your body's defense
system (immune system) to help your body
accept the new kidney
 Selling Price is Rs: 1,230/Box
 Competitors: GSK, AHP

8. Blenco - Injection
 Bleomycin is used to treat cancer. It works by slowing or
stopping the growth of cancer cells.
 This medication may also be used to control the build-
up of fluid around the lungs caused by tumors that have
spread to the lungs. For this condition, bleomycin is
placed in the space around the lungs through a chest
tube.
 SellingPrice is Rs: 1,245/(Vial/Box)
 Competitors: Cipla Pharma, Atco Pharma

9. Carbotionol - Injection
 Carboplatin is used to treat various types of cancer. It is a
chemotherapy drug that contains platinum.
 It is used alone or in combination with other medications
to slow or stop cancer cell growth.
 Selling Price is Rs: 2,225/Box
 Competitors: Atco, BioPharma, Pfizer, Cipla

10. Daunocin
 Daunorubicin is used to treat leukemia and other
cancers.
 It works by slowing or stopping the growth of cancer
cells.
 Selling Price is Rs: 637/Box
 Competitors: No Competition

11. Duticin Injection
 Dacarbazine is used to treat certain types of cancer,
such as skin cancer that has spread (metastatic
malignant melanoma) and Hodgkin's disease.
 It is a cancer chemotherapy drug that is used alone or
with other medications to slow or stop cancer cell
growth.
 Selling Price is Rs: 556/Box
 Competitors: Medinet, Al Habib Pharma

12. Etopul Injection
 Etoposide is used alone or in combination with
other chemotherapies to treat certain forms of
cancer (e.g., small cell lung cancer).
 Etoposide works by slowing cancer cell growth. It is
also commonly known as VP-16.
 Selling Price is Rs: 6,265 (10Apm/Box)
 Competitors: Bio, Atco, AHP, Pfizer

13. Gemcit Injection
 Gemcitabine is used alone or with other
treatments/medications to treat certain types of cancer
(including breast, lung, pancreatic).
 It is a chemotherapy drug that works by slowing or
stopping the growth of cancer cells.
 Selling Price is Rs: 10,100/Box
 Competitors: AHP, Ely Lille, Novartis, Ferozsons

14. Kunyrin Injection
 This medication is used to treat or prevent
serious blood cell disorders caused by high
toxicity drugs.
 It may also be used with a certain cancer drug
to treat patients with colon cancer.
 Selling Price is Rs: 5,562/box (10amp=1box)
 Competitors: AHP, Atco, Bio Pharma

15. Onfran Injection
 This medication is used alone or with other
medications to prevent nausea and vomiting
caused by cancer drug treatment
(chemotherapy) and radiation therapy.
 It is also used to prevent and treat nausea and
vomiting after surgery. It works by blocking one of
the body's natural substances (serotonin) that
causes vomiting.
 Selling Price is Rs: 3,840/Box (5vial/box)
 Competitors: GSK, Bio Pharma, Novartis, Zafa

16. Unistin Injection
 Cisplatin is used to treat various types of cancer. It
is a chemotherapy drug that contains platinum.
 It is used alone or in combination with other
medications to slow or stop cancer cell growth.
 Selling Price is Rs: 4,250/Box (10Vial/Box)
 Competitors: AHP, Atco, Cipla, Pfizer

17. Unitaxel - Injection
 Paclitaxel is used to treat various types of cancer.
 It is a cancer chemotherapy drug that works by slowing
or stopping cancer cell growth.
 Selling Price is Rs: 5936/box (1vial/box)
 Competitors: Atco, BioPharma, Ferozsons

18. Utoral Injection
 Fluorouracil is used to treat various types of cancer.
 It is a chemotherapy drug that is used alone or in
combination with other medications to slow or stop
cancer cell growth.
 Selling Price is Rs: 1,335/box (10Vial/Box)
 Competitors: AHP, Atco, Bio Pharma

19. Vinracine Injection
 Vincristine is used to treat various types of
cancer.
 It is a cancer chemotherapy drug that is usually
used with other chemotherapy drugs to slow or
stop cancer cell growth.
 Selling Price is Rs: 3,393/Box (10vial/box)
 Competitors: Pharmatech

20. Zycram Injection
 Zycram is used to treat various types of cancer. It is a
chemotherapy drug that works by slowing or stopping cell
growth.
 Zycram also works by decreasing your immune system's
response to various diseases. It is used to treat a certain type
of kidney disease in children after the failure of other
treatments
 Selling Price is Rs: 358/Box
 Competitors: No Competitors

21. Distribution Channel

22. Manufacturer
(Korea United
Pharma)
Importer
(Onco Care
Pharma)
DHL
(Courier
Service)
Supply to
Institutions
Karachi
Other Cities
Manufacturer
(Korea United
Pharma)
Importer
(Onco Care
Pharma)
DHL
(Courier
Service)
Local
Distributor
Supply to
Institutions

23. PROMOTION

24. Promotional Material
Pen & Card Holder
 These Material will be provided to the Target Customers (Doctors)
every year.
PlannerBall-Pen

25. Calendar
Promotional Material
Card USB

26. Cancer Awareness Seminars

27. Cancer Awareness Seminars
 Cancer Awareness Seminar In Collaboration with SIUT and Agha
Khan Hospital.
 Venue: Pearl Continental Hotel, Karachi
 Invitation to 30 A Class Doctors all over Pakistan
 Invite all the students of Medical University to create awareness
about the cancer related diseases.

28. Sponsorship To Global Educational
Conference
 Sponsoring our A Class Doctors to attend Global Cancer
Seminars/Conference:

29. Cancer Awareness via Social Media

30. Sales Plan

31. Responsibilities of VP Sales
 Onco Care is striving to cure cancer with breakthrough medicines
that have been produced abroad in world-class laboratories
 The Oncology Unit and Business Unit have been designed to work
with a mutual commitment to delivering highly innovative and
commercially viable cancer therapies
 The VP Sales is responsible for achieving the company’s revenue
and growth targets
 The VP Sales manages multiple Regional Sales Managers (RSM) who
supervise their individual sales team within their territory
 Pharmaceutical sales representative is in charge of developing
relationships with pharmacists and doctors
 Division of customers on the basis of geographic territories is most
apt for Onco Care Pharmaceutical
31

32. National Network Territory

33. Target Institutions – REGION 1
REGION 1
KARACHI HYDERABAD
Aga Khan University Hospital Nuclear Institute of Medicine &
Radiotherapy (NIMRA)
Liaquat national hospital LARKANA
Jinnah post medical centre Larkana Institute of Nuclear Medicine &
Radiotherapy (LINAR)
Ziauddin Hospital QUETTA
Baqai Hospital Centre for Nuclear Medicine &
Radiotherapy (CENAR)
Karachi Institute of radiotherapy and
nuclear medicine (KIRAN)
Bolan medical complex
Civil Hospital NAWABSHAH
Children Cancer Hospital NORIN HOSPITAL
SIUT (Oncology unit)

34. Target Institutions – REGION 2
REGION 2
MULTAN BAHAWALPUR
Nishter Hospital Victoria Hospital
Multan institute of nuclear medicine
and radiotherapy (MINAR)
Bahawalpur Institute for nuclear
Oncology (BINO)
DERA ISMAIL KHAN
Dinar Hospital

35. Target Institutions – REGION 3
REGION 3
LAHORE FAISALABAD
Shaukat khannum Memorial Hospital Allied Hospital
Institute of Nuclear Medicine and
Oncology (INMOL)
Punjab Institute of Nuclear Medicine
(PINUM)
Mayo Hospital GUJRANWALA
Jinnah Hospital GINUM Hospital

36. Target Institutions – REGION 4
REGION 4
RAWALPINDI / ISLAMABAD ABBOTABAD
Nuclear Medicine Oncology &
Radiation Institute (NORI)
INOR Hospital
Combine Military Hospital
Shifa International Hospital

37. Target Institutions – REGION 5
REGION 5
PESHAWAR SWAT
Khyber medical college and hospital SINOR Cancer Hospital
Institute of Radiotherapy and nuclear
medicine (IRNUM)

38. Target Doctors (City Wise)
S.NO CITY DOCTORS
1 KARACHI 14
2 HYDERABAD 3
3 LARKANA 3
4 QUETTA 4
5 NAWABSHAH 3
6 MULTAN 4
7 BAHAWALPUR 4
8 DERA ISMAIL KHAN 3
9 LAHORE 13
10 FAISALABAD 4
11 GUJRANWALA 3
12 ISLAMABAD 8
13 ABBOTABAD 3
14 PESHAWAR 4
15 SWAT 3
TOTAL 76
KARACHI
19%
HYDERABAD
4%
LARKANA
4%
QUETTA
5%
NAWABSHAH
4%
MULTAN
5%
BAHAWALPUR
5%
D.I.KHAN
4%
LAHORE
17%
FAISALABAD
5%
GUJRANWALA
4%
ISLAMABAD
11%
ABBOTABAD
4%
PESHAWAR
5%
SWAT
4%
TARGET DOCTORS

39. Sales Forecasting Technique
 An assessment of the general economic conditions of Pakistan has
been carried out
 According to the State Bank's Annual Report on the State of
Economy for the year 2012-13, Pakistan’s economy grew at 3.6 per
cent and inflation fell to single-digit in Fiscal Year 2013
 The Real GDP growth rate in Fiscal 2014 is likely to remain between
3%-4%
 Industry sales have also been taken into account and 20% market
share target has been identified
 The Jury of Executive Opinion was employed to determine the Total
Market Potential all over Pakistan
 The first year annual market share target has been developed and is
forecasted
39

40. Market Potential
s.no PRODUCTS. TOTAL POTENTIAL (UNITS)
1 AZAFRINE 50 mg Tab. 60,000
2 BLEONCO- S 15mg Inj. 22,000
3 CARBOTINOL 150 mg/15 ml Inj. 18,000
4 DUTICIN 200mg Inj. 30,000
5 DAUNOCIN 20 mg Inj. 18,000
6 ETOPUL 100 mg/5ml Inj. 20,000
7 GEMCIT 1000 mg 15,000
8 ISOXAN 2gm Inj 35,000
9 KUNYRIN 50 mg/5ml Inj. 6,000
10 ONFRAN 8 mg Inj 40,000
11 UTORAL 500 mg/10ml Inj. 40,000
12 UNISTIN 50 mg/50ml Inj. 50,000
13 UNITAXEL 30 mg/5ml Inj. 36,000
14 VINRACINE 2 mg/2ml Inj. 5,000
15 ZYCRAM 1000 mg Inj. 60,000
TOTAL 455,000

41. National Sales Forecast
s.no PRODUCTS. SALES FORECAST (Units) SALES FORECAST
(Rs)
1 AZAFRINE 50 mg Tab.
12,000
11,768,640
2 BLEONCO- S 15mg Inj.
4,400
5,159,280
3 CARBOTINOL 150 mg/15 ml Inj.
3,600
9,718,800
4 DUTICIN 200mg Inj.
6,000
2,910,038
5 DAUNOCIN 20 mg Inj.
3,600
2,374,736
6 ETOPUL 100 mg/5ml Inj.
4,000
23,055,200
7 GEMCIT 1000 mg
3,000
43,228,000
8 ISOXAN 2gm Inj
7,000
10,288,000
9 KUNYRIN 50 mg/5ml Inj.
1,200
18,777,312
10 ONFRAN 8 mg Inj
8,000
30,720,000
11 UTORAL 500 mg/10ml Inj.
8,000
11,533,363
12 UNISTIN 50 mg/50ml Inj.
10,000
38,692,000
13 UNITAXEL 30 mg/5ml Inj.
7,200
30,962,176
14 VINRACINE 2 mg/2ml Inj.
1,000
15,335,456
15 ZYCRAM 1000 mg Inj.
12,000
4,296,000
TOTAL 91,000 258,819,002

42. Market Potential vs Sales Forecast
60,000
22,000
18,000
30,000
18,000
20,000
15,000
35,000
6,000
40,000
40,000
50,000
36,000
5,000
60,000
12,000
4,200
3,600
6000
3,600
4,000
3,000
7,000
1,200
8,000
8,000
10,000
7,200
1,000
12,000
0 10,000 20,000 30,000 40,000 50,000 60,000 70,000
AZAFRINE
BLEONCO- S
CARBOTINOL
DUTICIN
DAUNOCIN
ETOPUL
GEMCIT
ISOXAN
KUNYRIN 50
ONFRAN
UTORAL
UNISTIN
UNITAXEL
VINRACINE
ZYCRAM
Sales Forecast Market Potential

43. Regional Sales Forecast
REGION 1
32%
REGION 2
8%
REGION 3
24%
REGION 4
8%
REGION 5
28%
s.no PRODUCTS. REGION
1
REGION
2
REGION
3
REGION
4
REGION
5
TOTAL
1 AZAFRINE 50 mg Tab. 3,840 960 2,880 960 3,360 12,000
2 BLEONCO- S 15mg Inj. 1,408 352 1,056 352 1,232 4,400
3 CARBOTINOL 150 mg Inj. 1,152 288 864 288 1,008 3,600
4 DUTICIN 200mg Inj. 1,920 480 1,440 480 1,680 6,000
5 DAUNOCIN 20 mg Inj. 1,152 288 864 288 1,008 3,600
6 ETOPUL 100 mg/5ml Inj. 1,280 320 960 320 1,120 4,000
7 GEMCIT 1000 mg 960 240 720 240 840 3,000
8 ISOXAN 2gm Inj 2,240 560 1,680 560 1,960 7,000
9 KUNYRIN 50 mg/5ml Inj. 384 96 288 96 336 1,200
10 ONFRAN 8 mg Inj 2,560 640 1,920 640 2,240 8,000
11 UTORAL 500 mg/10ml Inj. 2,560 640 1,920 640 2,240 8,000
12 UNISTIN 50 mg/50ml Inj. 3,200 800 2,400 800 2,800 10,000
13 UNITAXEL 30 mg/5ml Inj. 2,304 576 1,728 576 2,016 7,200
14 VINRACINE 2 mg/2ml Inj. 320 80 240 80 280 1,000
15 ZYCRAM 1000 mg Inj. 3,840 960 2,880 960 3,360 12,000
TOTAL 29,120 7,280 21,840 7,280 25,480 91,000

44. Selling Process
Phase 1
1. Prospecting and Qualifying
2. Pre Approach
3. Approach
4. Need Identification
5. Presentation
6. Objection Handling
7. Closing the Process
8. Follow up

45. Phase 1:
1) Prospecting and Qualifying
 Region 1: 27 doctors.
 Region 2: 11 Doctors.
 Region 3: 20 Doctors.
 Region 4: 11 Doctors.
 Region 5: 7 Doctors.

46. 2) Pre-Approach
 Onco Care gathers the additional information about the
potential customers
 The method that will be used to gather such information
is decided

47. 3) Approach
 Representatives create good first impression
 Males dress in a full sleeved white button shirt and tie with dress
pants
 Women dress in traditional clothes
 Hand shake
 They come fully prepared with all the gathered information such as
the prospect’s company, products etc. eg: Agha Khan
 They maintain interactive environment during presentation

48. 4) Need identification
 Identifying the needs of prospects and then fulfilling those needs by
offering the right product
 Side effects of cancer drugs include Nausea, Diarrhea, Hair loss,
Hearing loss, skin and nail changes and fatigue
 Competitive advantage: low price, reduced side effects

49. 5) Presentation
 Visual aid: Power Point (Bar Charts, Graphs)
 Reports, Testimonials and Examples
 Providing Drug Manual
 Focus is on product features (competitive advantages; low price
and reduced side effects)

50. 6) Objection handling
 Responding to the questions raised by the prospects
 Questions asked regarding low price and ingredients of medicines
 Objections (comparison method)

51. 7) Closing the process
 Closing technique our sales force uses is the gift close
technique
 The inducements provided by Onco Care are: Pens,
Card Holders, Calendars, USB and Planners

52. 8) Follow up
 This step is to ensure that the medicines purchased are
being used by the hospitals/medical institutes
 This is done via email, telephone and personal visits by
salesperson of Onco Care

53. Training of Sales Force

54. Training of Sales Force
 The purpose for carrying out sales training activities is to keep the
sales force inspired, motivated and enable it to continue to
produce results
 Having a sound understanding of your product, your competition,
and the most effective sales techniques can make an average
sales rep into a star performer
 They need training not only about their own products, services,
company history, and existing clients, but also about selling
techniques, technology, and software
54

55. Product Knowledge
 Product knowledge is one of the most significant requirements of a sales force
 RSMs will be trained in such a way that they will have adequate information
regarding Onco’s products and any special manufacturing process that might
be relevant to the doctor
 TheProduct & Training Manager will deliver information to them through regularly
held meetings
 This information will equip sales managers to be able to satisfy any possible
queries doctors might have
 Proper knowledge regarding the product will keep them ahead of their
competitors
 This will ensure that the RSMs have an internal driving force that will motivate
them to work harder
 Product knowledge is vital as representatives of the company need to have
adequate information about their own products, and also those of competitors
55

56. Query Handling
 Role clarity refers to a clear understanding of the responsibilities of one’s
job
 Eliminate any ambiguities that exist amongst RSMs regarding their job by
outlining areas of responsibility
 A “queries and possible concerns” session will be held every two weeks
to address any possible concerns that the managers may have
 Establishing and managing an effective query process is an integral
component of ensuring data integrity
 A query is defined as a question posed to a provider to obtain
additional and clarifying documentation to improve the completeness
of the data
 Monthly seminars regarding Query Handling will be held where RSM’s will
be provided supplementary information
56

57. Compensation Plan

58. Compensation Plans
1. Chief executive officer:
 Salary: Will be given a monthly salary of Rs235,000. (inclusive of allowances)
 Bonus: The CEO will be given an annual bonus of approximately Rs: 50,000 for the first
year. It will going to increase in the second year if the company performs well
throughout the year and able to achieve the yearly targets.
Employee benefits and paid expenses:
 Will be provided with a chauffeured car(Corolla).
 Fuel allowance of Rs 15,000.
 Cell phone service.
 Office space.
 Personal assistant.
 Allowed leave of 15 days annually.
 DELL laptop

59. 2. Personal Assistant:
 Salary: A montly Salary of Rs65,000 (inclusive of allowances)
 Bonus: The employee will be given an annual bonus of Rs30,000.

3. Compensation Plan of VP Sales:
 Salary: Total Salary of Rs 155,000 (inclusive of allowances)
 Bonus: The employee will be given an annual bonus of Rs30,000

Employee benefits and paid expenses:
 VP Sales will be provided with a Honda City Car.
 Fuel Allowance
 Annual leave of 12 days.
 Cell phone services.
 Office space.

60. 4. Compensation plan of VP Marketing:
 Salary: Total Salary of Rs155,000. (inclusive of allowances)
 Bonus: The employee will be given an annual bonus of Rs30,000
Employee benefits and paid expenses:
 VP Marketing will be provided with a Honda City Car.
 Office Space
 Cell phone services
 Annual leave of 12 days.
 Fuel Allowance

61. 5. Compensation plan of Finance Manager:
 Total Salary: Rs100,000 (inclusive of allowances)
 Bonus: A bonus of Rs15,000 will be given when financial statements
at year end have been formulated.
Employee benefits and paid expenses:
 Office space.
 Cell phone services
 A Dell laptop for work related services

62. 6. Compensation plan of HR manager:
 Total Salary: Rs80,000. (inclusive of allowances)
 Bonus: An annual bonus of Rs15,000 will be given.
Paid expenses:
 Office space.
 Necessary equipment needed to design compensation plans and
packages.
 Funds will be provided to conduct the training programs for the
employees
7. Compensation plan of Marketing Manager:
 Total Salary: Rs 58,000. (inclusive of allowances)
 Bonus: Annual bonus of Rs15,000 will be given.

63. 8. Compensation plan of RSM’s:
 Total Salary: Rs55,000/Month will be given.
 Incentive: A monthly incentive of Rs15,000 will be given on achieving
the targets
Paid expenses:
 Fuel allowance
 Cell phone services.
 Travelling expenses.

64. 9. Compensation plan of the cashier:
 Salary: A monthly base salary of Rs36,000 will be given.
 Bonus: An annual bonus of Rs10,000 will be given.
10. Compensation plan of the business analyst:
 Salary: A monthly base salary of Rs29,000 will be given.
 Bonus: An annual bonus of Rs10,000 will be given.
11. Compensation plan of Accountant:
 Salary: A monthly salary of Rs30,000 will be given.
 Bonus: An annual bonus of Rs10,000 will be given.

65. 12. Compensation plan of the Distribution Manager:
 Salary: A monthly Salary of Rs43,000 will be given.
 Bonus: An annual bonus of Rs10,000 will be given.

66. Budgeting

67. Administrative Cost
Administrative Cost:
Office Rent Bungalow: 81 - B Block 6
Shahrah Faisal
12 Months 1,00,000 Rs. 12,00,000
Business Insurance Jubilee Insurance 12 Months 30,000 Rs. 360,000
Office Set-up Cost tables, chairs, meeting room,
shelves paint, lights etc)
12 months 1,000,000 Rs. 1,000,000
Total Administrative Cost Rs. 2,560,000

68. Cost of Inventory
Import Price (RS)
PRODUCTS: 615 7,355,400
AZAFRINE 50 mg Tab. 623 3,227,140
BLEONCO- S 15mg Inj. 1,113 6,076,980
CARBOTINOL 150 mg/15 ml Inj. 278 1,818,120
DUTICIN 200mg Inj. 319 1,486,540
DAUNOCIN 20 mg Inj. 3,133 14,411,800
ETOPUL 100 mg/5ml Inj. 5,050 27,017,500
GEMCIT 1000 mg 1,000 6,430,000
ISOXAN 2gm Inj 2,781 11,735,820
KUNYRIN 50 mg/5ml Inj. 1,920 19,200,000
ONFRAN 8 mg Inj 667 7,203,600
UTORAL 500 mg/10ml Inj. 2,125 24,182,500
UNISTIN 10 mg/20ml Inj. 2,968 19,351,360
UNITAXEL 30 mg/5ml Inj. 1,696 9,582,400
VINRACINE 2 mg/2ml Inj. 179 2,685,000
Total Cost: Rs. 161,761,876

69. Technology Cost
Technology Cost:
Laptops:
Higher Management --> HP Latops 7 60,000 420,000
Staff Fujitsu 10 35,000 350,000
Printers Samsung LaserJet 5 8,000 40,000
Internet Connection Wi-tribe 6 1500 9000
Scanner Genx Super Scan 5 3,990 19,950
Total cost for Technology: Rs. 838,950

70. Marketing Budget
S.No Description Total
Promtional Material
1 Pen 2,300
2 Planner Dairy 22,800
3 Calendar 15,200
4 Pen & Card Holder 34,200
5 Card USB (FREE)
74,500
Cancer Awareness Seminar (1Day)
1 Hotel Stay 320,000
2 Conference Hall (FREE) -
3 Lunch/Dinner 108,000
428,000
Global Educational Conference (7 Day Plan)
1 Hotel Stay 997,500
2 Conference Fee 1,500,000
3 Allowances (Per day) 525,000
3,022,500
TOTAL 3,525,000

71. Training Cost
Annual Budget for Sales training Program to be held at Pearl Continental Karachi
Per Day/Night Total for 3 Days
Booking Charges for meeting rooms Rs. 10000 Rs. 30,000
Per night charges for 5 rsms Rs. 6600 Rs. 19,800
Lunch and Dinner charges Rs 2000 Rs. 30,000
Miscelleneous Expenses Rs. 2000 Rs. 6,000
Total for One quarter RS. 85,800
Total for One Year Rs. 343,200

72. First Year
TOTAL COST Rs, 191,346,030

73. Alfalah Karobar Finance
 Business Loan
 Mark up rate: 8%
 Duration: 10 years
Year Principal
Payment
Interest
(8%)
TOTAL
1 19,134,603 1,530,768 20,665,371
2 19,134,603 1,530,768 20,665,371
3 19,134,603 1,530,768 20,665,371
4 19,134,603 1,530,768 20,665,371
5 19,134,603 1,530,768 20,665,371
6 19,134,603 1,530,768 20,665,371
7 19,134,603 1,530,768 20,665,371
8 19,134,603 1,530,768 20,665,371
9 19,134,603 1,530,768 20,665,371
10 19,134,603 1,530,768 20,665,371
TOTAL 191,346,030 15,307,682 206,653,712

74. Profitability Analysis
Sales 258,819,002
Less: Trade Discount (10%) 25,881,900
Cost of Sales 161,761,876
Gross Profit 71,175,226
Less: Operating Expenses
Administrative Expense 2,560,000
Marketing expense 3,525,000
Salaries, Benefits etc 7,456,000
Technology Expense 838,950
Training Expense 247,200
Total Expense 14,627,150
56,548,076
Import Duty (5%) 5,176,380
Income before Tax 51,371,696
Taxation (10%) 10,352,760
Income after Tax 41,018,936
BANK Loan 20,665,371
NET INCOME 20,353,565

75. Thank You 